Empower Advisory Group
AMRX icon

Empower Advisory Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Empower Advisory Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,391
Closed -$136K – 496
2023
Q4 		$136K Buy
+22,391
New +$99.7K ﹤0.01% 470

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empower Advisory Group's AMRX Position: Q1 2024 in Review

Empower Advisory Group sold out of Amneal Pharmaceuticals (AMRX) in Q1 2024, closing a stake of 22,391 shares — an estimated $136K sold.

Empower Advisory Group first reported a position in AMRX in Q4 2023 and held it in 1 quarter. The position peaked at $136K in Q4 2023. 175 funds tracked by Wall St. Rank hold AMRX as of Q1 2024.

  • Empower Advisory Group reported no remaining Amneal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Empower Advisory Group sold 22,391 Amneal Pharmaceuticals shares in Q1 2024, an estimated $136K.
  • Empower Advisory Group first reported a position in Amneal Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Empower Advisory Group's Amneal Pharmaceuticals position peaked at $136K in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2024.

Based on Empower Advisory Group's 13F filing for Q1 2024, filed 2 May 2024.